Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (<i>CTNNB1</i>) mutations.

ABSTRACT:

Aims

Mutations affecting exon 3 of the β-catenin (CTNNB1) gene result in constitutive activation of WNT signalling and are a diagnostic hallmark of several tumour entities including desmoid-type fibromatosis. They also define clinically relevant tumour subtypes within certain entities, such as endometrioid carcinoma. In diagnostics, β-catenin immunohistochemistry is widely used as a surrogate for CTNNB1 mutations. Yet, it is often difficult to assess in practice, given that the characteristic nuclear translocation may be focal or hard to distinguish from the spillover of the normal membranous staining.

Methods

We therefore examined lymphoid enhancer-binding factor 1 (LEF1) immunostaining, a nuclear marker of WNT activation that serves as a potential surrogate f

SUBMITTER: Hewer E 

PROVIDER: S-EPMC12772540 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature